Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The Journal of pharmacy and pharmacology

• Publication date

  2001-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1211/0022357011775992PMID 11370706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Torasemide

  2012cited by this paper
• New trends in thromboxane and prostacyclin modulators.

  2000cited by this paper
• Antagonism of the TXA2 receptor by seratrodast: a structural approach.

  1999cited by this paper
• Protein modelling for all.

  1999cited by this paper
• Thromboxane A2 Receptor Antagonism in Man and Rat by a Sulphonylcyanoguanidine (BM‐144) and a Sulphonylurea (BM‐500)

  1999cited by this paper
• Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.

  1998cited by this paper
• SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling

  1997cited by this paper
• Thromboxane A2 and related prostaglandins in airways

  1997cited by this paper
• SHELXL: high-resolution refinement.

  1997cited by this paper
• Synthesis and pharmacology of pyrid-3-ylsulfonylcyanoguanidines as diuretics

  1995influential reference
• N2‐Cyano‐N1‐isopropyl‐N3‐[4‐(3‐methylphenylamino)‐3‐pyridylsulfonyl]guanidine

  1995cited by this paper
• 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.

  1994cited by this paper
• Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na+ 2Cl- K+ cotransporter inhibitors

  1994influential reference
• Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.

  1994cited by this paper
• Antagonism of the human thromboxane A2 receptor by an anti-asthmatic agent AA-2414.

  1994cited by this paper
• Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction.

  1993influential reference
• Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta.

  1993cited by this paper
• Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists.

  1993cited by this paper
• Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes.

  1992cited by this paper
• Characterization of Thromboxane A2/Prostaglandin H2 Receptors in Porcine Coronary Artery -The Inhibitory Effect of a Novel Dibenzoxepin Derivative, KW-3635

  1992cited by this paper
• A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery.

  1992cited by this paper
• Structures du cyclohexyl-1 [(cycloheptylamino-4 pyridyl-3)sulfonyl]-3 urée et de l'hydrogénonitrate du cyclohexyl-1 [(cyclooctylamino-4 pyridyl-3)sulfonyl]-3 urée

  1991cited by this paper
• Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review.

  1990cited by this paper
• The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist.

  1989cited by this paper
• Binding of thromboxane A2/prostaglandin H2 agonists to human platelets

  1987cited by this paper
• Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist.

  1987cited by this paper
• Overview of physiological and pathophysiological effects of thromboxane A2.

  1987cited by this paper
• Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets.

  1987cited by this paper
• Thromboxane A2 synthase inhibitors. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acids.

  1986cited by this paper
• Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.

  1985cited by this paper
• Synthesis and structure of the platelet aggregation factor thromboxane A2

  1985cited by this paper
• BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.

  1984cited by this paper
• COMPARISON OF THE ACTIONS OF U‐46619, A PROSTAGLANDIN H2‐ANALOGUE, WITH THOSE OF PROSTAGLANDIN H2 AND THROMBOXANE A2 ON SOME ISOLATED SMOOTH MUSCLE PREPARATIONS

  1981cited by this paper
• Structure cristalline et moléculaire d'un diurétique dérivé de l'alkyl-1 [(phénylamino-4 pyridyl-3)sulfonyl]-3 urée: la torasémide (C16H20N4SO3)

  1978cited by this paper
• Die Constitution der sogenannten Dithiocyansäure und Persulfocyansäure

  year unknowninfluential reference

• Visible-light organophotoredox-mediated intermolecular formal [4 + 2] cycloadditions of arylcyclobutylamines with olefins.

  2023cites this paper
• 1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia

  2021cites this paper
• Human cytochrome P450 enzymes 5–51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition – toxic effects and benefits

  2018cites this paper
• Tests for Anxiolytic Activity

  2015cites this paper
• Application of dimethyl N-cyanodithioiminocarbonate in synthesis of fused heterocycles and in biological chemistry

  2014cites this paper
• Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A₂ receptor antagonists.

  2013cites this paper
• Prostaglandins and Other Lipid Mediators M-573 inhibits the development of early atherosclerotic lesions in Apo E eficient mice by blocking TP receptors and thromboxane synthase

  2011cites this paper
• Inhibitory effects of resveratrol on platelet activation induced by thromboxane a(2) receptor agonist in human platelets.

  2011cites this paper
• Animal models of anxiety and anxiolytic drug action.

  2010cites this paper
• Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity.

  2008cites this paper
• Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity.

  2008cites this paper
• BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.

  2007cites this paper
• Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor.

  2007cites this paper
• From the design to the clinical application of thromboxane modulators.

  2006cites this paper
• Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.

  2006cites this paper
• Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor.

  2006cites this paper
• In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist

  2004cites this paper
• Effect of BM-573, a dual thromboxane synthase inhibitor and TP receptor antagonist, in a porcine model of acute pulmonary embolism

  2004cites this paper
• In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist

  2004cites this paper
• In Vitro and in Vivo Pharmacological Characterization of BM-613 [N-n-Pentyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist

  2004cites this paper
• Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.

  2004cites this paper
• Effect of BM-573 [N-Terbutyl-N′-[2-(4′-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, in a Porcine Model of Acute Pulmonary Embolism

  2004cites this paper
• A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors.

  2003cites this paper
• BM-573, a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, Prevents Pig Myocardial Infarction Induced by Coronary Thrombosis

  2003cites this paper
• Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function.

  2003cites this paper
• Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.

  2001cites this paper